Epidemiology and Challenges of HBV/HIV Co-Infection Amongst HIV-Infected Patients in Endemic Areas: Review

References

• Barth RE, Huijgen Q, Taljaard J, Hoepelman IM. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infectious Diseases. 2010;14:e1024–e1031. doi:10.1016/j.ijid.2010.06.013
   Web of Science ®Google Scholar
• World Health Organization. Management of hepatitis B and HIV co infection. 2011. Available from: http://www.euro.who.int/__data/assets/pdf_file/0011/152012/e95792.pdf. Accessed April 23, 2021.
   Google Scholar
• Alberti A, Clumeck N, Collins S, et al. Short statement of the first European consensus conference on the treatment of chronic Hepatitis B and C in HIV Co infected patients. J Hepatol. 2005;42:615–624. doi:10.1016/j.jhep.2005.03.003
   PubMed Web of Science ®Google Scholar
• Alter M. Epidemiology of viral hepatitis and HIV co-infection. J Hepathology. 2006;44:S6–9.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Prevention and control of viral hepatitis infection. Available from: https://apps.who.int/iris/handle/10665/130012. Accessed April 26, 2021
   Google Scholar
• Lacombe K, Rockstroh J. HIV and viral hepatitis co infections: advances and challenges. Gut. 2004;61(1):i47ei58.
   Google Scholar
• World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Available from: https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. Accessed April 23, 2021.
   Google Scholar
• UNAIDS, Joint United Nations Programme on HIV/AIDS. Seizing the moment - Tackling entrenched in equalities to end epidemics. Geneva: UNAIDS; 2020. Available from: https://www.un.org/sexualviolenceinconflict/wp-content/uploads/2020/07/report/global-aids-update-seizing-the-moment-tackling-entrenched-inequalities-to-end-epidemics/2020_global-aids-report_en.pdf. Accessed 29.04.2021.
   Google Scholar
• Modi A, Feld J. Viral hepatitis and HIV in Africa. AIDS Review. 2007;9:25–39.
   PubMed Web of Science ®Google Scholar
• Chun HM, Mesner O, Thio C, et al. HIV outcomes in Hepatitis B virus coinfected individuals on HAART. J Acquir Immune Defic Syndr. 2014;66(2):197–205. doi:10.1097/QAI.0000000000000142
   PubMed Web of Science ®Google Scholar
• McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005;25(1):3–8. doi:10.1055/s-2005-915644
   Web of Science ®Google Scholar
• World Health Organization. UNAIDS report on the global AIDS epidemic 2013. 2013; Available from: https://www.who.int/hiv/pub/me/unaids_global_report/en/. Accessed April 23, 2021.
   Google Scholar
• Valla D. EASL International Consensus Conference of Hepatitis B, 13–14 September, 2002 Geneva, Switzerland. J Hepatol. 2003;38:533–540.
   PubMedGoogle Scholar
• Motamedifar M, Taheri M, Lankarani KB, et al. The prevalence and risk factors of hepatitis delta virus in HIV/HBV Co-Infected Patients in Shiraz, Iran, 2012. Iran J Med Sci September. 2015;40(5).
   Google Scholar
• Deressa T, Damtie D, Fonseca K, et al. The burden of hepatitis B virus (HBV) infection, genotypes and drug resistance mutations in human immunodeficiency virus positive patients in Northwest Ethiopia. PLoS One. 2017;12(12):e0190149. doi:10.1371/journal.pone.0190149
   Web of Science ®Google Scholar
• Chambal LM, SamoGudo E, Carimo A, et al. HBV infection in untreated HIV-infected adults in Maputo, Mozambique.2017. PLoS One. 2017;12(7):e0181836. doi:10.1371/journal.pone.0181836
   PubMed Web of Science ®Google Scholar
• Salpini R, Fokam J, Ceccarelli L, et al. High Burden of HBV-Infection and Atypical HBV Strains Among HIV Infected Cameroonians. Curr HIV Res. 2016;14. doi:10.2174/1570162X13666150930114742
   Web of Science ®Google Scholar
• Sorianoa V, Puotib M, Bonacinic M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV–HBV International Panel. AIDS. 2005;19:221–240.
   Web of Science ®Google Scholar
• Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-co infected patients. J Antimicrobial Chemotherapy. 2006;57:815–818. doi:10.1093/jac/dkl068
   PubMed Web of Science ®Google Scholar
• Singh KP, Crane M, Audsley J, Lewin SR. HIV-Hepatitis B virus co-infection: epidemiology, pathogenesis and treatment. AIDS. 2017;31(15):2035–2052. doi:10.1097/QAD.0000000000001574
   Google Scholar
• Alo MN, Alhassan HM, Saidu AY, Ugah UI, Umar FA. Cd4 T cell count in patients concomitantly infected with HIV and Hepatitis B Virus in Sokoto State, Nigeria. World J Medical Sciences. 2013;8(3):296–299.
   Google Scholar
• Ethiopian Public Health Institute. Ethiopia population-based HIV impact assessment (EPHIA) 2017-2018.Available from: https://phia.icap.columbia.edu/wp-content/uploads/2020/11/EPHIA_Report_280820_High-Res.pdf. Accessed April 23, 2021.
   Google Scholar
• Ayana DA, Mulu A, Mihret A, et al. Hepatitis B virus seromarkers among HIV infected adults on ART: an unmet need for HBV screening in eastern Ethiopia. PLoS One. 2019;14(12):e0226922.
   Web of Science ®Google Scholar
• Pappoe F, Hagan CKO, Yeboah DO. Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care. BMC Infect Dis. 2019;19:380. doi:10.1186/s12879-019-4027-y
   Web of Science ®Google Scholar
• Gede Foundation. Seroprevalence of hepatitis B and C infection among the HIV-positive population in Abuja, Nigeria. Afr Health Sci. 2012;12(3):312–317. doi:10.4314/ahs.v12i3.10.
   Web of Science ®Google Scholar
• Ogwu-Richard SO, Ojo DA, Akingbade OA, Okonko IO. Triple positivity of HBsAg, anti-HCV antibody, and HIV and their influence on CD4+ lymphocyte levels in the highly HIV infected population of Abeokuta, Nigeria. Afr Health Sci. 2015;15(3):719. doi:10.4314/ahs.v15i3.4
   Web of Science ®Google Scholar
• Coffie PA, Tchounga BK, Bado G, et al. Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West Africa. BMC Infect Dis. 2017;17:466. doi:10.1186/s12879-017-2568-5
   PubMed Web of Science ®Google Scholar
• Chonco F, Rangiah S. Susceptibility to hepatitis B infection, hepatitis B/HIV co-infections and hepatitis B immunity in HIV-positive patients starting HAART in Durban, South Africa. South African Family Practice. 2019;61(2):65–68. doi:10.1080/20786190.2018.1518023
   Web of Science ®Google Scholar
• Matthews PC, Beloukas A, Malik A, et al. Prevalence and characteristics of Hepatitis B Virus (HBV) Coinfection among HIV-Positive Women in South Africa and Botswana. PLoS One. 2015;10(7):e0134037. doi:10.1371/journal.pone.0134037
   PubMed Web of Science ®Google Scholar
• Lok A, McMahon B. Chronic Hepatitis B. Hepatology. 2007;45:2.
   Web of Science ®Google Scholar
• Rehermann B, Nascimbeni M. Immunology of Hepatitis B virus and Hepatitis C virus infection. Nature Reviews Immunology. 2005;5:215–229. doi:10.1038/nri1573
   PubMed Web of Science ®Google Scholar
• Shimelis T, Tassachew Y, Tadewos A, et al. Coinfections with hepatitis B and C virus and syphilis among HIV-infected clients in Southern Ethiopia: a cross-sectional study. HIV/AIDS HIV/AIDS Research Palliative Care. 2017;9:203–210. doi:10.2147/HIV.S150795
   Web of Science ®Google Scholar
• Thio C, Lsmeaton L, Saulynas M, et al. Characterization of HIV-HBV co-infection in a multi-national HIVinfected cohort. AIDS. 2013;27(2):191–201. doi:10.1097/QAD.0b013e32835a9984
   Web of Science ®Google Scholar
• Abera B, Zenebe Y, Mulu W, Kibret M, Kahsu G. Sero prevalence of hepatitis B and C viruses and risk factors in HIV infected children at Felegehiwot referral hospital, Ethiopia. BMC Res Notes. 2014;7:83.
   Google Scholar
• Chang JJ, Sirivichayakul S, Avihingsanon A, et al. Impaired quality of the Hepatitis B Virus (HBV)-Specific T-cell response in human immunodeficiency virus type 1-HBV co infection. J Virol. 2009;7649–7765.
   Web of Science ®Google Scholar
• Chun HM, Roediger MP, Hullsiek KH, et al. Hepatitis B Virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis. 2012;205:185–193.
   PubMed Web of Science ®Google Scholar
• Drake A, Mijch A, Sasadeusz J. Immune reconstitution Hepatitis in HIV and Hepatitis B coinfection, despite lamivudine therapy as part of HAART. HIV/AIDS CID. 2004;39.
   Google Scholar
• Re VL, Newcomb CW, Carbonari DM, et al. Determinants of liver complications among HIV/Hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr. 2019;82(1):71–80. doi:10.1097/QAI.0000000000002094
   Web of Science ®Google Scholar
• Hafkin JS, Osborn MK, Localio AR, et al. Incidence and risk factors for incomplete HBV DNA Suppression in HIV/HBV-coinfected patients initiating tenofovir based therapy. J Viral Hepat. 2014;21(4):288–296. doi:10.1111/jvh.12142
   Web of Science ®Google Scholar
• World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendation for public health approach. Geneva:WHO; 2016. Available from www.who.int. Accessed November 5, 2020.
   Google Scholar
• Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H. Hepatology Clinical Hand Book. 4th ed. flying publisher; 2013:69–77.
   Google Scholar
• Cheruvu S, Marks K, Talal AH. Understanding the pathogenesis and management of Hepatitis B/HIV and Hepatitis B/Hepatitis C virus co infection. Clinical Liver Disease. 2007;11:917–943.
   PubMedGoogle Scholar
• Weldemhret L, Asmelash T, Belodu R, Gebreegziabiher D. Sero-prevalence of HBV and associated risk factors among HIV positive individuals attending ART clinic at Mekelle hospital, Tigray, Northern Ethiopia. AIDS Res Ther. 2016;13(1):6.
   Web of Science ®Google Scholar
• Khamduang W, Graffin CG, Huong NNG, et al. Long-term Hepatitis B Virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand. PLoS One. 2012;7(7):e42184. doi:10.1371/journal.pone.0042184
   Web of Science ®Google Scholar